The Florida State University Research Foundation, Inc

Emory University

Children's Healthcare of Atlanta, Inc.

Children's Heatlhcare of Atlanta

Chaofeng Dai

Binghe Wang

Krishna Damera

Alexander Draganov

Xingyue Ji

Didier Merlin

Yueqin Zheng

Emilie Viennois

Weixuan Chen

Danzhu Wang

Chunhao Yang

Yong Chu

Nanting Ni

Phang-Cheng Tai

Xiaochuan Yang

Guojing Sun

Lubing Gu

Jinshan Jin

Yinghsin Hsieh

Ying-Ju Ritter

Jianmei Cui

Arpana S Chaudhary

Lifang Wang

Muxiang Zhou

Carbon monoxide-releasing organic molecules are described herein. The molecules can be synthesized prior to administration (e.g., ex vivo) or formed in vivo. In those embodiments where the molecules are formed in vivo, reactants are administered under physiological conditions and undergo a cycloaddition reaction to form a product which releases carbon monoxide. In applying such reactions for therapeutic applications in vivo, the cycloaddition and CO release typically occur only under near-physiological or physiological conditions. For example, in some embodiments, the cycloaddition reaction and/or release of carbon monoxide occur at a temperature of about 37&#xb0; C. and pH of about 7.4. Pharmaceutical compositions and methods for release carbon monoxide are also described.

Carbon monoxide-releasing molecules for therapeutic applications and methods for the preparation and use thereof

Rhein analogues that exhibit anti-proliferative activity, particular against cancer cells, are described herein. In some embodiments, the compounds contain a flat or planar ring system. Such rings system by facilitate non-covalent binding of the compounds to the DNA complex, such as by intercalation. In some embodiment, the compounds contain a flat or planar ring system as described above and one or more substituents which are alkylating moieties, electrophilic groups or Michael acceptors or groups which contain one or more alkylating moieties, electrophilic groups and/or Michael acceptors. The compounds described herein can also contain one more functional groups to improve the solubility of the compounds.

Anthraquinone analogs and methods of making and using thereof

Carbon monoxide-releasing organic molecules are described herein. The molecules can be synthesized prior to administration (e.g., ex vivo) or formed in vivo. In those embodiments where the molecules are formed in vivo, reactants are administered under physiological conditions and undergo a cycloaddition reaction to form a product which releases carbon monoxide. In applying such reactions for therapeutic applications in vivo, the cycloaddition and CO release typically occur only under near-physiological or physiological conditions. For example, in some embodiments, the cycloaddition reaction and/or release of carbon monoxide occur at a temperature of about 37 C and pH of about 7.4. Pharmaceutical compositions and methods for release carbon monoxide are also described.

Carbon monoxide-releasing molecules for therapeutic applications and methods of making and using thereof

Inhibitors of SecA, and methods of making and using thereof, are described herein. The compounds described herein can be used to treat or prevent microbial infections, such as bacterial infections.

SecA inhibitors and methods of making and using thereof

Disclosed are conjugates that can bind to one or more site on cancer cell surface, for example, surface proteins, compound specific receptors and carbohydrates that comprise the surface of specific cell types. The disclosed conjugates can thereby serve as indicators identifying the presence of cancerous tissue.

Cellular recognition conjugates and methods of use for the histological analysis of cancer tissue using MALDI-MS imaging

Growing community of inventors

Atlanta, GA, United States of America

Chaofeng Dai